Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Common Equity (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Common Equity for 5 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 116.04% to $29.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.7 million, a 116.04% increase, with the full-year FY2025 number at $19.0 million, changed N/A from a year prior.
  • Common Equity was $29.7 million for Q4 2025 at Neuphoria Therapeutics, up from $12.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $40.8 million in Q2 2022 to a low of $12.5 million in Q3 2025.
  • A 4-year average of $22.6 million and a median of $20.6 million in 2025 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 45.65% in 2023, then soared 116.04% in 2025.
  • Neuphoria Therapeutics' Common Equity stood at $40.8 million in 2022, then crashed by 45.65% to $22.2 million in 2023, then tumbled by 37.95% to $13.7 million in 2024, then skyrocketed by 116.04% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Common Equity are $29.7 million (Q4 2025), $12.5 million (Q3 2025), and $19.0 million (Q2 2025).